Search | Clinical Trials Finder

Conditions: IBS (Irritable Bowel Syndrome), Bloating, Abdominal Pain, Gut Health
Interventions: FODMAP-targeting digestive enzyme blend, Placebo; Dietary Supplement · Other
Lead sponsor: Kiwi Health Inc; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions: Placebo, Linaclotide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,722 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 52
States / cities: Huntsville, Alabama • North Little Rock, Arkansas • Phoenix, Arkansas + 49 more

Conditions: Irritable Bowel Syndrome With Constipation
Interventions: Virtual Reality; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Irritable Bowel Syndrome
Interventions: IBS Group, Healthy Control Group; Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2025
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Villanova, Pennsylvania

Conditions: Abdominal Pain/ Discomfort, Irritable Bowel Syndrome
Interventions: Music intervention; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Irritable Bowel Syndrome
Interventions: Olorinab, Placebo; Drug
Lead sponsor: Arena Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 69
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 60 more

Conditions: Irritable Bowel Syndrome Characterized by Constipation
Interventions: Linaclotide, Placebo; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 79
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more

Conditions: Irritable Bowel Syndrome
Interventions: Blautix, Placebo; Biological · Other
Lead sponsor: 4D pharma plc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 24
States / cities: Huntsville, Alabama • Phoenix, Arizona • North Hollywood, California + 21 more

Conditions: IBS - Irritable Bowel Syndrome
Interventions: SynerGI, Sham VR; Device
Lead sponsor: Christopher Almario; Other
Eligibility: 10 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 2
States / cities: Los Angeles, California • Cleveland, Ohio

Conditions: Irritable Bowel Syndrome
Interventions: Rifaximin 550 MG, Low FODMAP Diet; Drug · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Post-infectious Irritable Bowel Syndrome, Irritable Bowel Syndrome
Interventions: Not listed
Lead sponsor: University of Nevada, Reno; Other
Eligibility: 18 Years to 100 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Reno, Nevada

Conditions: Irritable Bowel Syndrome
Interventions: Usual Care (Control Group), Comprehensive Self-Management (CSM); Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 70 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions: SYN-010 21 mg, SYN-010 42 mg, Placebo; Drug
Lead sponsor: Theriva Biologics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Functional Constipation, Irritable Bowel Syndrome With Constipation
Interventions: Linaclotide, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 79
States / cities: Birmingham, Alabama • Foley, Alabama • Saraland, Alabama + 62 more

Conditions: Irritable Bowel Syndrome
Interventions: FODMAP; Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: IBS - Irritable Bowel Syndrome, IBD - Inflammatory Bowel Disease
Interventions: MIndful Jazz, Reggae Stereotypes, Traditional Mindfulness, Pain psychoeducation; Behavioral
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Orange, California

Conditions: Irritable Bowel Syndrome With Constipation
Interventions: Linaclotide Dose A, Linaclotide Dose B, Linaclotide Dose C, Linaclotide Approved Adult Dose, Matching Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 46
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 39 more

Conditions: IBS - Irritable Bowel Syndrome, Diarrhea
Interventions: Mirtazapine, Placebo; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Diarrhea Predominant Irritable Bowel Syndrome
Interventions: Serum-Derived Bovine Immunoglobulin, Placebo; Dietary Supplement · Other
Lead sponsor: Connecticut Children's Medical Center; Other
Eligibility: 8 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Pediatric Abdominal Pain
Interventions: Cognitive Behavioral Therapy & Social Learning, Education and Support; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 7 Years to 12 Years
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 3
States / cities: Chapel Hill, North Carolina • Seattle, Washington • Tacoma, Washington

Conditions: IBS - Irritable Bowel Syndrome
Interventions: Yogic breathing intervention; Behavioral
Lead sponsor: Texas State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Marcos, Texas

Conditions: Malignant Neoplasms of Independent (Primary) Multiple Sites
Interventions: Tongue Assessment, Stool Sample, Questionnaires, Holter Monitor, Yogurt; Other · Behavioral · Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Irritable Bowel Syndrome, IBS
Interventions: Nutrition/Mind-Body Coaching; Behavioral
Lead sponsor: Beth Israel Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Irritable Bowel Syndrome With Diarrhea
Interventions: CIN-103, Placebo; Drug
Lead sponsor: CinPhloro Pharma, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 53
States / cities: Dothan, Alabama • Huntsville, Alabama • Phoenix, Arizona + 45 more

Search by objective public record fields.

A Study Evaluating the Impact of Regular FODMAP-targeting Digestive Enzyme Blend Use on Gastrointestinal Symptoms in Individuals With Self-Reported Bloating

A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

A Study of Virtual Reality and Linaclotide for IBS-C

Pilot Study of the Physiological Effects of an Integrative Medicine Approach in Irritable Bowel Syndrome

The Mechanism Underlying the Analgesic Effect of the Music of IBS Pain

Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)

A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

A Trial for New Treatment of Adult Participants With Irritable Bowel Syndrome

RCT of VR Therapy for IBS

A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing

Characterizing Protein Biomarkers of Post-infection Irritable Bowel Syndrome

Nursing Management of Irritable Bowel Syndrome (IBS) 2008

A Study of the Effect of SYN-010 on Subjects With IBS-C

Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)

Diet Reintroduction Study in Irritable Bowel Syndrome

Relaxation Music for Chronic Pain

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation

Novel Pilot Study to Treat Symptoms of IBS With Diarrhea Using Combination Therapy of a Low-FODMAP Diet and a Neuromodulator

Safety and Tolerability of Serum Derived Bovine Immunoglobulin in Children With Diarrhea Predominant IBS

Managing Childhood Abdominal Pain

Yogic Breathing and IBS

The Effect of Yogurt in Cancer Patient With Moderate Gastrointestinal (GI) Symptoms

Integrative Approaches to Managing Irritable Bowel Syndrome (IBS)

Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).